Your browser doesn't support javascript.
loading
The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier, Bernard; Porta, Camillo; Eisen, Tim; Belsey, Jonathan; Gibson, Damilola; Morgan, Jonathan; Motzer, Robert.
Afiliación
  • Escudier B; a Department of Oncological Medicine , Institut Gustave Roussy , Villejuif , France.
  • Porta C; b Medical Oncology , University of Pavia and La Istituti Clinici Scientifici Maugeri , Pavia , Italy.
  • Eisen T; c Department of Oncology , Cambridge University Health Partners , Cambridge , UK.
  • Belsey J; d JB Medical Ltd , Sudbury , UK.
  • Gibson D; e Medical Affairs , EUSA Pharma , Hemel Hempstead , UK.
  • Morgan J; e Medical Affairs , EUSA Pharma , Hemel Hempstead , UK.
  • Motzer R; f Genitourinary Oncology Service, Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
Expert Rev Anticancer Ther ; 18(11): 1113-1124, 2018 11.
Article en En | MEDLINE | ID: mdl-30084668
INTRODUCTION: The efficacy of VEGF-targeting therapies in clinical trials led to their recommendation in clinical guidelines for use across the advanced or metastatic renal cell carcinoma (RCC) treatment landscape, however, tolerability (including off-target effects) has remained a challenge. Tivozanib is a selective inhibitor of all three VEGFRs, with limited off-target interaction, which demonstrates efficacy with improved tolerability relative to multikinase VEGFR-TKIs. Areas covered: Covered here is the clinical development of tivozanib in advanced RCC, including the pivotal Phase III, multicenter, open-label, randomized clinical study comparing tivozanib with sorafenib for the treatment of VEGF- and mTOR therapy-naïve advanced RCC patients. Also covered are ongoing trials, exploring the efficacy and safety of tivozanib in the setting of refractory disease and the utility of tivozanib in combination with checkpoint inhibitors for advanced RCC. Combination of a VEGFR-TKI and immunotherapy is promising in advanced RCC, if the treatment regimens have acceptable tolerability. Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Quinolinas / Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Quinolinas / Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido